Table 3. Treatment-emergent adverse events according to the preferred term (safety population).
| TEAEs | Testa (n = 24) | Referenceb (n = 23) | |
|---|---|---|---|
| Eye disorders | |||
| Colour blindness acquired | 1 | ||
| Photophobia | 21 | 18 | |
| Vision blurred | 2 | ||
| Visual impairment | 1 | 1 | |
| Investigations | |||
| Blood glucose increased | 1 | ||
| Lymphocyte count decreased | 1 | ||
| Urine oxalate increased | 1 | ||
| White blood cells urine positive | 1 | ||
| Nervous system disorders | |||
| Headache | 2 | ||
| Respiratory, thoracic and mediastinal disorders | |||
| Nasal congestion | 1 | ||
| Vascular disorders | |||
| Dizziness | 3 | 3 | |
| Epistaxis | 1 | ||
| Total | 30 | 28 | |
aVorico® Injection 200 mg.
bVfend® IV 200 mg.
TEAE, treatment-emergent adverse event.